These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 8517688)

  • 1. Postantibiotic effects of amikacin and ofloxacin on Mycobacterium fortuitum.
    Tsui SY; Yew WW; Li MS; Chan CY; Cheng AF
    Antimicrob Agents Chemother; 1993 May; 37(5):1001-3. PubMed ID: 8517688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Minimal bactericidal and inhibitory concentrations of ofloxacin on Mycobacterium fortuitum at pH 7 and 5: therapeutic implications.
    Yew WW; Kwan SY; Ma WK; Lui KS
    Tubercle; 1990 Sep; 71(3):205-8. PubMed ID: 2238127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single daily-dose ofloxacin monotherapy for Mycobacterium fortuitum sternotomy infection.
    Yew WW; Kwan SY; Ma WK; Khin MA; Mok CK
    Chest; 1989 Nov; 96(5):1150-2. PubMed ID: 2805845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Examining the Effect of Residual Amikacin on Sputum Culture for Nontuberculous Mycobacteria.
    Eagle G; Brown K; Floto RA
    Am J Respir Crit Care Med; 2018 Jan; 197(2):267-269. PubMed ID: 28644036
    [No Abstract]   [Full Text] [Related]  

  • 5. Repurposing disulfiram to target infections caused by non-tuberculous mycobacteria.
    Das S; Garg T; Chopra S; Dasgupta A
    J Antimicrob Chemother; 2019 May; 74(5):1317-1322. PubMed ID: 30753528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of ofloxacin and amikacin in the treatment of sternotomy wound infection.
    Yew WW; Kwan SY; Ma WK; Aung-khin M; Mok CK
    Chest; 1989 May; 95(5):1051-5. PubMed ID: 2707062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative antimycobacterial activities of ofloxacin, ciprofloxacin and grepafloxacin.
    Vacher S; Pellegrin JL; Leblanc F; Fourche J; Maugein J
    J Antimicrob Chemother; 1999 Nov; 44(5):647-52. PubMed ID: 10552981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Etest for routine clinical antimicrobial susceptibility testing of rapid-growing mycobacteria isolates.
    Koontz FP; Erwin ME; Barrett MS; Jones RN
    Diagn Microbiol Infect Dis; 1994 Jul; 19(3):183-6. PubMed ID: 7821001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biological evaluation of diphenyleneiodonium chloride (DPIC) as a potential drug candidate for treatment of non-tuberculous mycobacterial infections.
    Singh AK; Thakare R; Karaulia P; Das S; Soni I; Pandey M; Pandey AK; Chopra S; Dasgupta A
    J Antimicrob Chemother; 2017 Nov; 72(11):3117-3121. PubMed ID: 28961864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antimicrobial activity of ofloxacin and other agents against mycobacterial isolates from postoperative sternotomy wounds.
    Yew WW; Kwan SY; Ma WK; Lui KS; Aung MK
    Clin Ther; 1989; 11(6):775-85. PubMed ID: 2611821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topical ciprofloxacin for treating nontuberculous mycobacterial keratitis.
    Hu FR; Luh KT
    Ophthalmology; 1998 Feb; 105(2):269-72. PubMed ID: 9479286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic activities of tigecycline with clarithromycin or amikacin against rapidly growing mycobacteria in Taiwan.
    Huang CW; Chen JH; Hu ST; Huang WC; Lee YC; Huang CC; Shen GH
    Int J Antimicrob Agents; 2013 Mar; 41(3):218-23. PubMed ID: 23312605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative in vitro and in vivo activity of fleroxacin and ofloxacin against various mycobacteria.
    Tomioka H; Sato K; Saito H
    Tubercle; 1991 Sep; 72(3):176-80. PubMed ID: 1771676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multisite reproducibility of results obtained by the broth microdilution method for susceptibility testing of Mycobacterium abscessus, Mycobacterium chelonae, and Mycobacterium fortuitum.
    Woods GL; Bergmann JS; Witebsky FG; Fahle GA; Wanger A; Boulet B; Plaunt M; Brown BA; Wallace RJ
    J Clin Microbiol; 1999 Jun; 37(6):1676-82. PubMed ID: 10325306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delivery of aerosolized liposomal amikacin as a novel approach for the treatment of nontuberculous mycobacteria in an experimental model of pulmonary infection.
    Rose SJ; Neville ME; Gupta R; Bermudez LE
    PLoS One; 2014; 9(9):e108703. PubMed ID: 25264757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Failure of the Amikacin, Cefoxitin, and Clarithromycin Combination Regimen for Treating Pulmonary Mycobacterium abscessus Infection.
    Ferro BE; Srivastava S; Deshpande D; Pasipanodya JG; van Soolingen D; Mouton JW; van Ingen J; Gumbo T
    Antimicrob Agents Chemother; 2016 Oct; 60(10):6374-6. PubMed ID: 27458221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibiotic resistance in
    Jayasingam SD; Zin T; Ngeow YF
    Int J Mycobacteriol; 2017; 6(4):387-390. PubMed ID: 29171453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of different test conditions on the susceptibility of Mycobacterium fortuitum and Mycobacterium chelonae to amikacin.
    Hansen KT; Clark RB; Sanders WE
    J Antimicrob Chemother; 1994 Mar; 33(3):483-94. PubMed ID: 8040113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In Vitro Antimicrobial Susceptibility of Nontuberculous Mycobacteria in Iran.
    Heidarieh P; Mirsaeidi M; Hashemzadeh M; Feizabadi MM; Bostanabad SZ; Nobar MG; Hashemi Shahraki A
    Microb Drug Resist; 2016 Mar; 22(2):172-8. PubMed ID: 26468990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimycobacterial Susceptibility Testing of Nontuberculous Mycobacteria.
    Brown-Elliott BA; Woods GL
    J Clin Microbiol; 2019 Oct; 57(10):. PubMed ID: 31315954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.